Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
Pfizer
Pharma
Alnylam sees Amvuttra as potential standard of care in ATTR-CM
At the ESC conference, Alnylam presented data from a key trial which assessed Amvuttra as a treatment for transthyretin amyloid cardiomyopathy.
Kevin Dunleavy
Aug 30, 2024 10:06am
AbbVie's Ubrelvy fares well warding off migraines in study
Aug 29, 2024 11:58am
GSK secures favorable Zantac court ruling in Delaware
Aug 28, 2024 8:10am
Pfizer unveils DTC virtual health platform PfizerForAll
Aug 27, 2024 11:00am
Moderna, Pfizer gain FDA nods for their adapted COVID vaccines
Aug 23, 2024 11:22am
J&J-Yuhan, Merck, biosecurity—Fierce Pharma Asia
Aug 23, 2024 10:05am
